Biontech and oncoc4 initiate pivotal phase 3 trial of bnt316/onc-392 program in metastatic nsclc

Mainz, germany, and rockville, maryland, usa, june 29, 2023 (globe newswire) — biontech se (nasdaq: bntx, “biontech”) and oncoc4, inc. (“oncoc4”) today announced that the first patient with non-small cell lung cancer (nsclc) has been treated in a pivotal phase 3 trial evaluating the companies' next-generation anti-ctla-4 antibody candidate bnt316/onc-392 (gotistobart). the trial is part of biontech's strategy to initiate multiple pivotal trials in 2023 and 2024.
BNTX Ratings Summary
BNTX Quant Ranking